Human Umbilical Cord Blood–Derived Stromal Cells: A New Resource in Hematopoietic Reconstitution in Mouse Haploidentical Transplantation

Zhang, C.; Chen, X.-H.; Zhang, X.; Kong, Peiyan; Peng, Xiaoyong; Li, Xue; Gao, Li; Wang, Q.Y.

doi:10.1016/j.transproceed.2010.08.052

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was significant heterogeneity among the studies (I 2 = 66.1%, P = 2.12×10 −18 ) (Figure 1 ). In addition, 29 studies involving 41 comparisons examined the effect of MSCs on aGVHD-associated clinical scores [ 14 , 15 , 17 , 19 , 20 , 22 , 24 , 27 , 28 , 33 , 34 , 36 – 39 , 42 , 44 , 46 , 47 , 49 – 52 , 55 , 57 – 59 , 61 , 62 ]. The pooled analysis indicated that aGVHD-associated clinical scores were significantly lower in the MSC groups than in the control groups (SMD = −3.60, 95% CI −4.43 to −2.76, P = 3.61×10 −17 ) (Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models

et al. 2016

View full text Add to dashboard Cite

A meta-analysis of animal models was conducted to evaluate the prophylactic effects of mesenchymal stem cells (MSCs) on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. A total of 50 studies involving 1848 animals were included. The pooled results showed that MSCs significantly reduced aGVHD-associated mortality (risk ratio = 0.70, 95% confidence interval 0.62 to 0.79, P = 2.73×10−9) and clinical scores (standardized mean difference = −3.60, 95% confidence interval −4.43 to −2.76, P = 3.61×10−17). In addition, MSCs conferred robust favorable prophylactic effects on aGVHD across recipient species, MSC doses, and administration times, but not MSC sources. Our meta-analysis showed that MSCs significantly prevented mortality and alleviated the clinical manifestations of aGVHD in animal models. These data support further clinical trials aimed at evaluating the efficacy of using MSCs to prevent aGVHD.

show abstract

Section: Resultsmentioning

confidence: 99%

Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models

et al. 2016

View full text Add to dashboard Cite

show abstract

“…With an established in vitro co-culture system [ 19 , 24 ] and a MRD mouse model, we investigate the effects of Cx43 expressed by BMSCs in preventing leukemia relapse. In this study, CX43 was over-expressed on hUCSC (a stable BMSC resource) and co-cultured with L615 leukemia cells.…”

Section: Discussionmentioning

confidence: 99%

“…Heparin was used as the anti-coagulant. The hUCSC were harvested as described previously [ 24 ]. In brief, mononuclear cells from human cord blood were obtained by Ficoll density gradient fractionation columns (density = 1.077 g/l Pharmacia Biotech, Uppsala, Sweden).…”

Section: Methodsmentioning

confidence: 99%

Increased expression of CX43 on stromal cells promotes leukemia apoptosis

et al. 2015

View full text Add to dashboard Cite

Connexin 43 (Cx43) induced apoptosis has been reported in solid tumors, but the effect of Cx43 expressed by bone marrow stromal cells (BMSC) in leukemia has not been fully investigated. Manipulating Cx43 expression could be a potential therapeutic strategy for leukemia. Here, we investigate the effect of Cx43 expressed by BMSCs (human Umbilical Cord Stem Cells over-expressed CX43, Cx43-hUCSC) on leukemia cells. When co-cultured with Cx43-hUCSC, leukemia cells show significant lower growth rate with increasing apoptosis activity, and more leukemia cells enter S phase. Functional assays of fluorescence recovery after photo bleaching (FRAP) showed improved gap junctional intercellular communication (GJIC) on leukemia cells when co-cultured with Cx43-hUCSC (p < 0.01). In a mouse minimal disease model, the mean survival time and mortality rate were significantly improved in mice transplanted with Cx43-hUCSC. Our results indicate that Cx43 expressed by BMSC induces apoptosis on leukemia cells. Small molecules or other pharmaceutical approaches for modulating Cx43 expression in BMSCs could be used for delaying relapse of leukemia.

show abstract

“…cell expansion and the formation of colony-forming unit (CFU). When mice were cotransplanted with haploidentical hematopoietic cells and hUCBDSC, the engraftment of hematopoietic cells was faster than in HSC-only control [125]. Recently, MSC in combination with SCF, TPO, and FGF-1 showed higher capacity of hematopoiesis enhancement compared to MSC alone, evidenced by more CFU formation in vitro, and rapid hematopoietic reconstitution in mice [126].…”

Section: Msc Enhances the Reconstruction Of Hematopoiesismentioning

confidence: 99%

Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis

Liu¹,

Sun

Wang

et al. 2011

Int J Hematol

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSC) have attracted the attention of scientists and clinicians due to their self-renewal, capacity for multipotent differentiation, and immunomodulatory properties. Some essential problems remain to be solved before the clinical application of MSC. Platelet lysate (PL) has recently been used as a substitute for FBS in MSC amplification in vitro to achieve clinically applicable numbers of MSC. In addition to promising trials in regenerative medicine, such as in the treatment of major bone defects and myocardial infarction, MSC have shown therapeutic effect other than direct hematopoiesis support in hematopoietic reconstruction. It has been confirmed that MSC promote hematopoietic cell engraftment and immune recovery after allogeneic hematopoietic stem cell transplantation, probably through the provision of cytokines, matrix proteins, and cell-to-cell contacts. Their suppressive effects on immune cells, including T cells, B cells, NK cells and DC cells, suggest MSCs as a novel therapy for GVHD and other autoimmune disorders. These cells thus present as promising candidates for cellular therapy in the fields of regenerative medicine, allogeneic hematopoietic stem cell transplantation, and autoimmune disorders.

show abstract

Human Umbilical Cord Blood–Derived Stromal Cells: A New Resource in Hematopoietic Reconstitution in Mouse Haploidentical Transplantation

Cited by 4 publications

References 31 publications

Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models

Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models

Increased expression of CX43 on stromal cells promotes leukemia apoptosis

Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis

Contact Info

Product

Resources

About